(4937) Stock Price

Waqoo uses digital marketing to plan, develop, and sell its own cosmetic brands, while also offering contract manufacturing services for blood-derived products in the regenerative medicine field. The company delivers products and services that provide options to people across both the cosmetics and medical-related sectors.

Its primary customers are individual consumers and clinics and beauty salons. On the cosmetics side, the company operates a subscription model that ensures consistent revenue. Waqoo generates revenue from both recurring subscription-based income and transaction-based income from contract manufacturing and wholesale sales.

The business is divided into two main segments: D2C (Direct-to-Consumer) and Medical Support. In the D2C segment, the company plans and sells its flagship brand "HADA NATURE" and hair growth product "sodatel." Waqoo handles everything from planning to sales in-house, excluding manufacturing. Through its subsidiaries, the company has integrated manufacturing technology and sales operations, and also promotes wholesale distribution of raw materials and cosmetics.

The company prioritizes high growth and increased corporate value as its core management objectives, with revenue expansion and improvements in operating profit and net income as key performance indicators. Specifically, it aims to build a stable revenue foundation through two complementary streams: recurring revenue from cosmetics subscription models (stock-type revenue) and transaction-based revenue from blood-derived processing services and wholesale sales of raw materials and cosmetics. To achieve this, the D2C (direct-to-consumer) business is reducing advertising spending and shifting toward a strategy that maximizes customer lifetime value.

The company has designated medical support and D2C as priority investment areas, pursuing differentiation in each. In medical support, it is strengthening its sales organization for blood-derived processing services through new hiring and establishing comprehensive support systems from partner clinic adoption through operation, aiming to increase the number of partner clinics and their utilization rates. In raw material sales, it is expanding OEM orders by leveraging high safety and quality standards as a competitive advantage.

To develop new markets and expand operations, the company is implementing upgraded versions of existing offerings and acquiring new customers. Specific initiatives include expanding partner clinics through regional sales representatives while investing in cost-efficient channels for flagship products such as the hair growth product "sodatel" based on detailed advertising data analysis to improve purchase rates and customer retention. Looking ahead, the company is also considering new business ventures, such as pharmaceutical product distribution, by leveraging existing resources.

The company positions technological innovation and digital utilization as critical management strategies. It is advancing functional improvements to blood-derived processing services, product development that integrates manufacturing technology with sales, and enhanced quality control, while strengthening data analytics in advertising and customer management to improve marketing efficiency. Through these efforts, the company aims to enhance competitiveness in both regenerative medicine and cosmetics sectors, pursuing sustainable growth and increased corporate value.